Black Rock Inc. Humacyte, Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Humacyte, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 7,140,014 shares of HUMA stock, worth $34.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

7,140,014

Previous 4,788,740 49.1%

Holding current value

$34.6 Million

Previous $14.9 Million 130.14%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$2.87 - $9.1 $6.75 Million - $21.4 Million	2,351,274 Added 49.1%	7,140,014 $34.3 Million
Q1 2024 May 10, 2024	SELL	$2.57 - $4.84 $284,110 - $535,057	-110,549 Reduced 2.26%	4,788,740 $14.9 Million
Q4 2023 Feb 13, 2024	BUY	$1.99 - $3.12 $793,617 - $1.24 Million	398,803 Added 8.86%	4,899,289 $13.9 Million
Q3 2023 Nov 13, 2023	BUY	$2.75 - $4.48 $538,947 - $877,994	195,981 Added 4.55%	4,500,486 $13.2 Million
Q2 2023 Aug 11, 2023	BUY	$2.86 - $4.97 $1.43 Million - $2.49 Million	501,265 Added 13.18%	4,304,505 $12.3 Million
Q1 2023 May 12, 2023	SELL	$2.11 - $3.25 $437,111 - $673,276	-207,162 Reduced 5.17%	3,803,240 $11.8 Million
Q4 2022 Feb 13, 2023	BUY	$2.02 - $3.62 $3.63 Million - $6.51 Million	1,799,047 Added 81.35%	4,010,402 $8.46 Million
Q3 2022 Nov 14, 2022	SELL	$1.22 - $5.14 $225,728 - $951,018	-185,023 Reduced 7.72%	2,211,355 $7.21 Million
Q2 2022 Aug 12, 2022	BUY	$3.21 - $7.86 $2.63 Million - $6.43 Million	818,459 Added 51.87%	2,396,378 $7.69 Million
Q1 2022 May 12, 2022	BUY	$4.65 - $7.4 $822,333 - $1.31 Million	176,846 Added 12.62%	1,577,919 $11.1 Million
Q4 2021 Feb 10, 2022	BUY	$7.25 - $11.6 $10.2 Million - $16.3 Million	1,401,073 New	1,401,073 $10.2 Million

Others Institutions Holding HUMA

# of Institutions

150

Shares Held

35.1M

Call Options Held

279K

Put Options Held

607K

View Full List

About Humacyte, Inc.

Ticker HUMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,007,000
Market Cap $499M
Description
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular ...

More about HUMA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account